PEPTIDEPEDIA
参加する
BPC-157 + KPV Blend: Separate Evidence, Untested Combination illustration
市販ブレンド
B 0032026-08-06

BPC-157 + KPV Blend: Separate Evidence, Untested Combination

すべてのブレンドBPC-157KPV
BPC-157 + KPV Blend: Separate Evidence, Untested Combination の理想的な構造図
B 003BPC-157 · KPV

配列から構築した理想化コンフォマー。実験構造でも予測構造でもありません。

証拠の内容は英語で管理されます。

Bottom line

A two-component research-peptide combination pairing BPC-157 (cytoprotective/angiogenic pentadecapeptide) with KPV (Lys-Pro-Val, anti-inflammatory tripeptide derived from alpha-MSH). Often marketed as a GI-focused alternative to broader blends, and as a component of KLOW70 (which adds GHK-Cu without TB-500). No published combination study exists.

No established or recommended human dose.

Name and formulation variability

Market contextClaimed compositionClaimed amountsVerification limits
Marketed pairBPC-157, KPVCommon listing: 10 / 10 mgSeller-dependent; no formulation standard
KLOW70 observationBPC-157, KPV, plus GHK-CuObserved listing: 10 / 10 / 50 mgSeller-declared; not the same composition as the standalone pair

This combination exists as a distinct pairing (especially in GI research contexts) or as KLOW70 (which adds GHK-Cu but omits TB-500). Composition varies.

Component evidence

ComponentSeparate evidenceCombination evidenceCompatibility
BPC-157 stage: GI and repair models, VEGFR2/NO and nitric-oxide pathway hypothesesNot identified for the pair; see shared caption belowNo co-formulation stability data
KPVIdentity and preclinical stage: Lys-Pro-Val, an alpha-MSH C-terminal fragment; inflammation models and PepT1 transport findings, including the Dalmasso 2008 colitis-model resultsNot identified for the pair; see shared caption belowInteraction and co-formulation evidence not identified

Shared combination-evidence caption: these are separate preclinical domains. They do not establish combined efficacy, safety, or compatibility.

Evidence domains without combination evidence
BPC-157 and KPV domains remain separate from the marketed pairingSeparate BPC-157 and KPV preclinical domains connect by dotted market lines to a pairing, which is blocked from a combination efficacy and safety box.BPC-157KPVGI modelsrepair modelspathway hypothesesalpha-MSH fragmentinflammation modelstransport findingsmarketed pairingcombination efficacy / safetyNOT TESTED AS A PAIRIDENTITYHYPOTHESIZED / SHARED DOMAINMARKET ASSOCIATIONEVIDENCE GAP
Domain labels summarize the page and do not assert clinical benefit. Legend: solid outlines identify the substances described on the page; dashed lines show hypothesized or shared biological domains; dotted lines show market association only; barred lines mark missing combination or compatibility evidence.
テキストによる説明

BPC-157 has separate evidence in GI models, repair models, and pathway hypotheses. KPV has a defined alpha-MSH fragment identity plus separate inflammation-model and transport findings. The labels meet only as a marketed pairing; efficacy and safety were not tested as a pair.

Combination-specific studies

No published study tests the BPC-157 + KPV combination. The rationale rests entirely on separate component evidence.

Safety and interaction uncertainties

  • KPV's NF-κB inhibition may theoretically delay resolution-phase inflammation

  • BPC-157's NO modulation may interact with anti-inflammatory pathways

  • No combination-specific safety data

  • Fixed-ratio blends prevent independent dose adjustment

Regulatory and product-quality notes

  • Neither component is FDA-approved

  • Both sold as "research use only"

  • KPV occasionally appears in cosmetic products

  • : BPC-157 is listed under S0. KPV is not explicitly named in the 2026 List; an athlete should obtain a case-specific determination rather than infer status from the blend or from KPV's peptide class.

Evidence gaps

The KLOW70 analysis covers the observed three-component name without conflating it with this pair. For sample-level verification limits, see Product quality, authenticity, and testing.

Sources

  1. AminoCore Research. KLOW Blend Analysis (for KLOW70 variant). https://aminocoreresearch.com/articles/klow-blend-bpc-157-tb-500-ghk-cu-kpv accessed 2026-08-06.

  2. Dalmasso G, et al. Am J Physiol Gastrointest Liver Physiol. 2008;295(1):G43-G54. PMID 18436621.

  3. Durham Peptides. Inside the KLOW Blend (section on KPV and BPC-157). https://www.durhampeptides.ca/post/inside-klow-blend-four-component-breakdown accessed 2026-08-06.

  4. BergdorfBio. KLOW Stack Guide (component details). https://bergdorfbio.com/en/us/guides/klow-stack-leitfaden accessed 2026-08-06.

  5. World Anti-Doping Agency. 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

専門家の声

専門家の見解

コメントは個人の見解であり、エビデンスレビューの一部ではありません。掲載は支持を意味しません。

この化合物について、本アトラスが受け入れる情報源 — 査読付き文献、大学・病院・医学会の発表、規制当局、署名入りサイエンスジャーナリズム — において、検証済みの専門家コメントは見つかりませんでした。

コメントがないことは、化合物に関するいずれの方向の証拠にもなりません。

ベンダー、クリニック、ソーシャルメディアの主張はポリシーにより除外され、コメントとしてカウントされません。

この化合物について、本アトラスの情報源において検証済みの専門家ビデオは見つかりませんでした。

ビデオコメントがないことは、化合物に関するいずれの方向の証拠にもなりません。

ベンダーとソーシャルメディアのビデオはポリシーにより除外され、カウントされません。

質問

What does the marketed BPC-157 plus KPV pairing contain?

The standalone pairing declares BPC-157 and KPV, but no recognized formulation standard defines it. Market declarations do not independently verify composition or quality.

Has the BPC-157 plus KPV combination been studied?

No published study of the specific pair was identified. Its proposed GI rationale comes from separate preclinical domains and is not a demonstrated combination result.

What safety uncertainties apply to BPC-157 plus KPV?

No combination-specific human safety, interaction, pharmacokinetic, or co-formulation stability evidence was identified. Neither component is FDA-approved for the marketed claims.

Is BPC-157 plus KPV the same as KLOW70?

No. The KLOW70 observation adds GHK-Cu, so it is a three-component market declaration rather than the standalone BPC-157 and KPV pair.

What kind of evidence exists for KPV separately?

KPV has a defined Lys-Pro-Val identity and separate preclinical inflammation-model and intestinal-transport findings. Those findings do not establish efficacy for the marketed pairing.

Can separate GI-model findings establish a benefit from the pair?

No. GI-model findings for each exact component do not test the combined material, so they cannot establish a clinical or preclinical benefit from the pair itself.